TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06350032: Open-label, Single-arm, Non-controlled Trial to Evaluate Safety and Tolerability of Treprostinil Sodium in Children Below the Age of 18 Years Diagnosed With Pulmonary Arterial Hypertension (PAH)

Sponsor: AOP Orphan Pharmaceuticals AG · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$1,980,048

Rescue Site Savings

+$1,320,032

Unlock Full NCT06350032 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06350032 Rescue Dossier →